Overview
TWST market data
Price History
TWST price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$1.30 Diluted earnings per share over the trailing twelve months.
- Beta
- 2.15 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $23.30 – $105.47 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $5.7K · P/B 3.59 · P/S 13.87.
Company News
Cathie Wood Is Selling This High-Flying Stock. Is It a Buy?The Motley Fool · Jul 20, 2026, 11:01 AM
Canaccord Genuity Maintains Buy on Twist Bioscience, Raises Price Target to $120Benzinga · Jul 14, 2026, 11:58 AM
Evercore ISI Group Downgrades Twist Bioscience to In-Line, Raises Price Target to $102Benzinga · Jul 6, 2026, 12:30 PM
Guggenheim Maintains Buy on Twist Bioscience, Raises Price Target to $107Benzinga · Jun 29, 2026, 2:10 PM
Barclays Maintains Overweight on Twist Bioscience, Raises Price Target to $95Benzinga · Jun 24, 2026, 2:50 PM
The Next Wave of Medical AI Could Mint More Millionaires Than the First -- Here Are the Stocks to OwnThe Motley Fool · Jun 19, 2026, 11:00 AM
Twist Bioscience Files Prospectus For Offering Mixed Shelf; Terms UndisclosedBenzinga · Jun 18, 2026, 8:15 PM
TD Cowen Maintains Buy on Twist Bioscience, Raises Price Target to $89Benzinga · Jun 15, 2026, 3:50 PM
Canaccord Genuity Initiates Coverage On Twist Bioscience with Buy Rating, Announces Price Target of $90Benzinga · Jun 15, 2026, 3:25 PM
Piper Sandler Initiates Coverage On Twist Bioscience with Overweight Rating, Announces Price Target of $85Benzinga · Jun 11, 2026, 11:11 AM